If glycemic target values are not reached, DPP-4 inhibitor may be replaced by a GLP-1 receptor agonist [15], with the advantages of higher HbA1c-lowering effect, without increasing the risk of hypoglycemia, and with the potential ability to reduce BW. Here, GLP1R is linked to Hypoglycemia.